/* CSS to help with ACF styling */ #page-header .h1 {color: #444;} #page-header h2.text-color-xsdn-color {color: #444;}
/* CSS to help with ACF styling */ #page-header .h1 {color: #fff;} #page-header h2.text-color-xsdn-color {color: #fff;}
/* CSS to help with ACF styling */ #page-header .h1 {color: ;} #page-header h2.text-color-xsdn-color {color: ;}
/* CSS to help with ACF styling */ #page-header {background-color: #031ac3;}
/* CSS to help with ACF styling */ #page-header {background: #fff url() center center; padding-top: 0px; padding-bottom: 0px; } @media all and (max-width: 4699px) and (min-width: 1925px) { .title-and-subtitle-background-image { padding-top: 3% !important; padding-bottom: 3% !important; } }
/* CSS to help with ACF styling */ #page-header {background: ;}

Texas HB 300

An expert healthcare lawyer provides an overview of Texas HB 300 and what you need to know to achieve compliance. She discusses where current compliance activities can be used or slightly modified to fulfill new requirements.

Reviewing Privacy & Security Procedures

FairWarning shares how to take full advantage of this opportunity to review your full compliance program, including user activity monitoring, OCR HIPAA Audits, data retention, Meaningful Use, fraud and misuse of data and legal defensibly.

According to the OCR sponsored HIPAA audits of 2012, user activity monitoring was the largest single shortfall in compliance with the Security Rule. You will learn how FairWarning addresses key areas of the audit protocols and how to satisfy the auditor’s requests and comply with the Security Rule


RELATED LEARNING CENTER

  • Increase Visibility Into Your Drug Diversion Monitoring Program
    Learn More
    Data Sheet
    Increase Visibility Into Your Drug Diversion Program
  • Addressing Drug Diversion in Healthcare - Where do I Start?
    Learn More
    Whitepaper
    Addressing Drug Diversion In Healthcare: Where Do I Start?
  • Learn More
    Data Sheet
    GDPR Mapping Guide